Efficacy and Safety of Risankizumab Compared With Apremilast in Patients With Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial. J of Skin 2023, 7 (6), s257. https://doi.org/10.25251/skin.7.supp.257.